Phase II Clinical Study of T-DM1 and Pyrotinib Maleate in Patients With HER2-positive Metastatic Breast Cancer Who Had Progressed on TKI Therapy
Not Applicable
Not yet recruiting
- Conditions
- HER2+ Advanced Breast Cancer Patients Progressing on TKI Therapy
- Interventions
- First Posted Date
- 2022-09-29
- Last Posted Date
- 2022-10-03
- Target Recruit Count
- 50
- Registration Number
- NCT05560308
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
- First Posted Date
- 2022-09-29
- Last Posted Date
- 2022-09-29
- Target Recruit Count
- 20
- Registration Number
- NCT05560334
- Locations
- 🇨🇳
Breast Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
Second Line Therapy for Advanced Intrahepatic Cholangiocarcinoma
Phase 2
Not yet recruiting
- Conditions
- Intrahepatic Cholangiocarcinoma
- Interventions
- Drug: FOLFOX
- First Posted Date
- 2022-09-10
- Last Posted Date
- 2022-09-10
- Target Recruit Count
- 60
- Registration Number
- NCT05535647
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
Sintilimab Combined With Regorafenib and HAIC in Patients With Colorectal Liver Metastasis
Phase 2
Not yet recruiting
- Conditions
- Liver MetastasisColorectal Cancer
- Interventions
- First Posted Date
- 2022-09-01
- Last Posted Date
- 2022-09-01
- Target Recruit Count
- 30
- Registration Number
- NCT05524155
Neoadjuvant Chemotherapytreatment of Locally Advanced Head and Neck Squamous Cell Carcinoma
Phase 2
Recruiting
- Conditions
- Head and Neck Squamous Cell CarcinomaNeoadjuvant Chemotherapy
- Interventions
- Drug: Triprilimab combined with TP
- First Posted Date
- 2022-08-31
- Last Posted Date
- 2022-08-31
- Target Recruit Count
- 122
- Registration Number
- NCT05522985
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
Sintilimab Combined With Lenvatinib Versus HAIC for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma
Phase 2
Recruiting
- Conditions
- Resectable Hepatocellular Carcinoma
- Interventions
- Drug: HAIC-FOLFOX
- First Posted Date
- 2022-08-29
- Last Posted Date
- 2022-08-29
- Target Recruit Count
- 60
- Registration Number
- NCT05519410
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
Study of DLL3-CAR-NK Cells in the Treatment of Extensive Stage Small Cell Lung Cancer
Phase 1
- Conditions
- SCLC, Extensive Stage
- Interventions
- Biological: DLL3-CAR-NK cells
- First Posted Date
- 2022-08-19
- Last Posted Date
- 2022-08-19
- Target Recruit Count
- 18
- Registration Number
- NCT05507593
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
Study of Osimertinib+Bevacizumab+Chemotherapy for EGFR+ Advanced Non-Small Cell Lung Cancer With Concurrent Mutations
Phase 2
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2022-08-19
- Last Posted Date
- 2022-08-19
- Target Recruit Count
- 50
- Registration Number
- NCT05507606
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
A Phase II Study of CRT Combined With QL1706 in ESCC Patients
- First Posted Date
- 2022-08-08
- Last Posted Date
- 2024-05-21
- Target Recruit Count
- 39
- Registration Number
- NCT05490719
- Locations
- 🇨🇳
Tianjin cancer hospital, Tianjin, Tianjin, China
Neoadjuvant Therapy of Camrelizumab Combined With Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
- First Posted Date
- 2022-07-27
- Last Posted Date
- 2022-07-27
- Target Recruit Count
- 39
- Registration Number
- NCT05476380
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute & Hospital, Tianjin, China
© Copyright 2025. All Rights Reserved by MedPath